Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06029439
Other study ID # NMRA-335140-501
Secondary ID KOASTAL-LT
Status Recruiting
Phase Phase 3
First received
Last updated
Start date November 10, 2023
Est. completion date September 2026

Study information

Verified date June 2024
Source Neumora Therapeutics, Inc.
Contact Study Contact
Email explore@koastalstudy.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), who provide informed consent, and who have no evidence of safety concerns that would preclude treatment with NMRA-335140 may be enrolled into this extension study.


Recruitment information / eligibility

Status Recruiting
Enrollment 650
Est. completion date September 2026
Est. primary completion date March 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Key Inclusion Criteria: Rollover participants are eligible for the study if the following inclusion criteria are met: - Completed a previous NMRA-335140 Phase 3 MDD study (NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303) according to the completion definition in the parent study protocol. - Signed an informed consent form (ICF) for this study. - Willing to comply with the contraception requirements described in the inclusion criteria of the parent study protocol. - Willing to comply with the concomitant medication/therapy restrictions described in the exclusion criteria of the parent study protocol. Key Exclusion Criteria: Rollover participants are excluded from the study if any of the following exclusion criteria are met: - Diagnosed with another Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) disorder that would have been exclusionary in the parent study (eg, personality disorder, bipolar 1 or 2, schizophrenia, any other psychotic disorder, or moderate or severe substance or alcohol use disorder [excluding nicotine]). - Considered to be at significant risk of suicide in the judgment of the Investigator. This includes participants who are actively suicidal (eg, any suicide attempts during the parent study) or are at serious suicidal risk as indicated by any current suicidal intent, including a plan, as assessed by the C-SSRS ("Since Last Visit" version, score of "YES" on suicidal ideation Item 4 or 5) and/or based on clinical evaluation by the Investigator; or are homicidal, in the opinion of the Investigator. - Non-adherent with study medication (took =70% of study drug over any 2-week visit interval) or procedures during the parent study. - Experienced treatment emergent adverse events (TEAEs) considered related to the study medication from the parent study and judged by the Investigator to be clinically significant to render the participant ineligible for enrollment. - Have an abnormality on ocular examination that would prohibit continued study participation as determined by the Investigator. - Use of disallowed concomitant medication or therapy that would have been exclusionary in the parent study, may compromise the safety of the participant, and/or confound the interpretation of protocol assessments. - Considered by the Investigator to be inappropriate for any other reason.

Study Design


Intervention

Drug:
NMRA-335140
Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.

Locations

Country Name City State
United States Neumora Investigator Site Allentown Pennsylvania
United States Neumora Investigator Site Austin Texas
United States Neumora Investigator site Austin Texas
United States Neumora Investigator Site Bellevue Washington
United States Neumora Investigator site Bellflower California
United States Neumora Investigator Site Berlin New Jersey
United States Neumora Investigator Site Boston Massachusetts
United States Neumora Investigator Site Brooklyn New York
United States Neumora Investigator Site Cedarhurst New York
United States Neumora Investigator Site Chicago Illinois
United States Neumora Investigator Site Colorado Springs Colorado
United States Neumora Investigator Site Dayton Ohio
United States Neumora Investigator Site Decatur Georgia
United States Neumora Investigator Site Everett Washington
United States Neumora Investigator Site Flowood Mississippi
United States Neumora Investigator Site Gainesville Florida
United States Neumora Investigator Site Garden Grove California
United States Neumora Investigator Site Glendale California
United States Neumora Investigator site Huntsville Alabama
United States Neumora Investigator Site Jacksonville Florida
United States Neumora Investigator Site Lafayette California
United States Neumora Investigator Site Las Vegas Nevada
United States Neumora Investigator Site Lauderhill Florida
United States Neumora Investigator Site Lauderhill Florida
United States Neumora Investigator site Little Rock Arkansas
United States Neumora Investigator Site Long Beach California
United States Neumora Investigator Site Los Angeles California
United States Neumora Investigator Site Maitland Florida
United States Neumora Investigator Site Marietta Georgia
United States Neumora Investigator Site Media Pennsylvania
United States Neumora Investigator Site Memphis Tennessee
United States Neumora Investigator site Methuen Massachusetts
United States Neumora Investigator site Miami Florida
United States Neumora Investigator site Miami Lakes Florida
United States Neumora Investigator Site Miami Lakes Florida
United States Neumora Investigator Site New York New York
United States Neumora Investigator Site New York New York
United States Neumora Investigator Site Oceanside California
United States Neumora Investigator Site Orange California
United States Neumora Investigator Site Orlando Florida
United States Neumora Investigator Site Phoenix Arizona
United States Neumora Investigator site Princeton New Jersey
United States Neumora Investigator Site Riverside California
United States Neumora Investigator Site Rogers Arkansas
United States Neumora Investigator Site Saint Charles Missouri
United States Neumora Investigator Site San Jose California
United States Neumora Investigator Site Savannah Georgia
United States Neumora Investigator site Springfield Massachusetts
United States Neumora Investigator Site Tampa Florida
United States Neumora Investigator Site Temecula California
United States Neumora Investigator Site Toms River New Jersey
United States Neumora Investigator site Towson Maryland
United States Neumora Investigator Site Warrenville Illinois
United States Neumora Investigator Site Watertown Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Neumora Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability assessments based on Treatment Emergent Adverse Events (TEAEs) and validated clinical scales An AE is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE). Clinically significant abnormalities in Clinical Laboratory Evaluations, ECGs, Vital Signs, Physical and Ophthalmological examinations, Corneal Specular Microscopy, Columbia Suicide Severity Rating Scale (C-SSRS), and Sexual Functioning Questionnaire-14 (CSFQ-14) will be reported as TEAEs. Up to 54 Weeks
Secondary Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score over time. Change from baseline in MADRS total score over time will be reported. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition. Baseline and up to Week 54
Secondary Change from Baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) total score over time The SHAPS is a 14-item participant-reported instrument which measures anhedonia. It has been shown to be valid and reliable in normal and clinical samples, with adequate construct validity, satisfactory test-retest reliability, and high internal consistency. The scale will be completed by the participant and reviewed by site personnel qualified to oversee completeness. Each of the 14 items has a set of 4 responses, 2 of which endorse agreement (Definitely Agree, Agree) and 2 of which endorse disagreement (Disagree, Strongly Disagree). A total score can be derived by summing the responses; items answered with strongly agree are coded as 1 while a strongly disagree response will be coded as 4. Therefore, scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia. Baseline and up to Week 54
Secondary Change from Baseline in the Patient Health Questionnaire-9 (PHQ-9) total score over time. Change from baseline in PHQ-9 total score over time will be reported. The 9-item PHQ-9 scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) diagnostic criteria for recurrent or single episode major depressive disorder (MDD) criteria and used both as a screening tool and a measure of response to treatment for depression. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Baseline and up to Week 54
Secondary Change from Baseline in PHQ-9 Anhedonia Item #1 over time. The PHQ-9 is a participant-rated assessment scale for the evaluation of depression symptoms over the past 2 weeks. The PHQ-9 is a reliable and valid measure of depression and depression severity. The questionnaire consists of 9 items and each item is scored from 0 to 3. Participants will be asked how often they have been bothered by symptoms over the past 2 weeks (Not at all [0], Several days [1], More than half the time [2], or Nearly every day [3]). Higher scores indicate higher levels of depression. Baseline and up to Week 54
Secondary Change from Baseline in the Hamilton Anxiety Rating Scale (HAM-A) total score over time. The HAM-A is a clinician-rated instrument administered to assess severity of anxiety, its improvement during the course of treatment, and the timing of such improvement. This instrument will be completed by qualified and trained Investigator site raters based on a semi-structured interview for his/her assessment of the participant. The scale consists of 14 items. Each item is rated on a scale of 0 (feeling not present) to 4 (very severe prevalence of the feeling). The HAM-A total score is the sum of the 14 items and the score ranges from 0 to 56. Baseline and up to Week 54
Secondary Change from Baseline in the Clinical Global Impression Scale of Severity (CGI-S) Change from baseline in the CGI-S total score over time will be reported. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. The CGI-S permits a global evaluation of the participant's condition at a given time. Baseline and up to Week 54
Secondary Clinical Global Impression Scale of Improvement (CGI-I) score at each timepoint The CGI-I scale is a clinician-rated instrument that measures the improvement of the participant's symptoms of depression. It is a 7-point scale where a score of 1 indicates that the participant is "very much improved," a score of 4 indicates that the participant has experienced "no change," and a score of 7 indicates that the participant is "very much worse." Baseline and up to Week 54
Secondary Percentage of participants whose MADRS total score decreased by greater than or equal to 50% from Baseline. Up to Week 54
Secondary Percentage of participants whose MADRS total score decreased to 10 or less. Up to Week 54
Secondary Change from baseline in the Sheehan Disability Scale (SDS) over time. The SDS is a participant-rated instrument which was developed to assess functional impairment in 3 related domains of work/school, social, and family life. It is a brief self rated tool where the participant rates the 3 items on an anchored 10 point visual analog scale. Following the participant's self assessment, the rater should review the Work/School and Days Lost items to confirm appropriateness of the selected rating by evaluating the impact of MDD symptoms across those sectors. The SDS may be administered via telephone assessment; however, the participant must be provided with a portable document format (PDF) copy of the assessment for reference of the visual analog scale when selecting their ratings. Baseline and up to Week 54
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4